Hahn Andrew W, Jamy Omer, Nunnery Sara, Yaghmour George, Giri Smith, Pathak Ranjan, Martin Mike G
Department of Internal Medicine, The University of Tennessee Health Science Center, Memphis, TN.
Department of Internal Medicine, The University of Tennessee Health Science Center, Memphis, TN.
Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):646-54. doi: 10.1016/j.clml.2015.07.646. Epub 2015 Aug 5.
Early mortality (EM) is all too frequent during induction chemotherapy for acute myeloid leukemia. Older patients shoulder an undue amount of this burden as a result of the inherent biology of their disease and increased comorbidities. EM rates in academic centers have seen a sharp decline over the past 20 years; however, data from population-based registries show that EM rates for the general population have significantly lagged behind. In this review, we analyze the data available on EM in academic centers and the general population, explore recent improvements in supportive care and the use of predictive models, and finally investigate the relationship between case volume and complications during chemotherapy.
在急性髓系白血病的诱导化疗期间,早期死亡率(EM)极为常见。由于疾病的内在生物学特性以及合并症增加,老年患者承受了过多此类负担。在过去20年中,学术中心的EM发生率急剧下降;然而,基于人群的登记数据显示,普通人群的EM发生率明显滞后。在本综述中,我们分析了学术中心和普通人群中有关EM的现有数据,探讨了支持治疗的近期改善情况以及预测模型的使用情况,最后研究了化疗期间病例数量与并发症之间的关系。